This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Monday's Health Winners & Losers

Regulatory updates and a slapdash sampling of news nudged a few biotech stocks in either direction on an overall flat start to the week.

Johnson & Johnson (JNJ - Get Report) on Monday submitted a new-drug application (NDA) to the Food and Drug Administration for paliperidone palmitate, an injection to treat and prevent symptoms of schizophrenia. The drug uses Elan's (ELN) NanoCrystal technology.

Alkermes (ALKS), which receives royalties on sales of Johnson & Johnson's current market-leading schizophrenia drug, Risperdal Consta, gave up 34 cents, or 2%, to $16.88.

Elan's shares traded up 48 cents, or 2.1%, to $23.26. Johnson & Johnson was trading up 70 cents, or 1.1%, to $65.

In a regulatory update, Adam's Therapeutics (ARXT) said Monday that it received an approvable letter from the FDA related to its NDA for Mucinex with Codeine extended-release tablets for cough associated with common cold, inhaled irritants and stable chronic bronchitis.

Adam's said the FDA requested additional data to support the use of the product with food and suggested various approaches to address the issue. The company doesn't expect the development to impact its financial guidance for fiscal 2008.

The company also said it expects fiscal 2008 profit to reach the high end of its guidance, as the FDA forces retailers to stop selling unapproved timed-release guaifenesin combination products that compete with its Mucinex and Mucinex DM. Shares rose $2.30, or 5.7%, to $42.88. The stock is a component of the Nasdaq biotechnology index, which was down 2.59, or 0.3%, to 888.26.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ELN $0.00 0.00%
ALKS $71.23 0.17%
JNJ $102.80 1.57%
AAPL $130.42 1.26%
FB $80.41 1.07%


DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs